IRIS
LAUDICELLA, Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.738
NA - Nord America 4.183
AS - Asia 2.422
SA - Sud America 761
Continente sconosciuto - Info sul continente non disponibili 224
AF - Africa 82
OC - Oceania 3
Totale 12.413
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.989
RU - Federazione Russa 2.624
SG - Singapore 1.041
BR - Brasile 622
IT - Italia 560
CN - Cina 521
IE - Irlanda 422
SE - Svezia 390
HK - Hong Kong 296
DE - Germania 169
VN - Vietnam 155
FR - Francia 127
GB - Regno Unito 103
IN - India 102
PL - Polonia 87
CA - Canada 85
AR - Argentina 51
FI - Finlandia 51
BD - Bangladesh 44
MX - Messico 37
NL - Olanda 36
AT - Austria 31
ID - Indonesia 31
JP - Giappone 31
ZA - Sudafrica 30
TR - Turchia 29
BE - Belgio 27
ES - Italia 26
IQ - Iraq 26
LT - Lituania 24
VE - Venezuela 19
CO - Colombia 15
EC - Ecuador 15
PK - Pakistan 15
PE - Perù 14
TN - Tunisia 14
AE - Emirati Arabi Uniti 13
MA - Marocco 13
UZ - Uzbekistan 13
AZ - Azerbaigian 11
CR - Costa Rica 11
IR - Iran 11
JM - Giamaica 11
MY - Malesia 11
PH - Filippine 11
UA - Ucraina 11
IL - Israele 10
PY - Paraguay 9
GT - Guatemala 8
HN - Honduras 8
SA - Arabia Saudita 8
CL - Cile 7
CZ - Repubblica Ceca 7
GE - Georgia 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
CH - Svizzera 5
KE - Kenya 5
KW - Kuwait 5
PA - Panama 5
PR - Porto Rico 5
PT - Portogallo 5
SV - El Salvador 5
EG - Egitto 4
GP - Guadalupe 4
JO - Giordania 4
NO - Norvegia 4
NP - Nepal 4
AL - Albania 3
BG - Bulgaria 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HU - Ungheria 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
OM - Oman 3
SN - Senegal 3
TH - Thailandia 3
AM - Armenia 2
AU - Australia 2
BB - Barbados 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
DZ - Algeria 2
EE - Estonia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
NG - Nigeria 2
NI - Nicaragua 2
RO - Romania 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
CM - Camerun 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
Totale 12.176
Salva come PNG Salva come JPEG
Città #
Moscow 797
Ashburn 695
Singapore 534
Dublin 420
Chandler 413
San Jose 387
Hong Kong 295
Nyköping 288
Dallas 265
Beijing 150
Council Bluffs 127
The Dalles 123
Los Angeles 122
Messina 115
Warsaw 78
Princeton 75
Munich 68
Medford 61
Santa Clara 59
São Paulo 59
Ho Chi Minh City 54
New York 51
Lauterbourg 45
Rome 42
Bremen 37
Des Moines 36
Redondo Beach 34
Buffalo 33
Hanoi 29
Hyderabad 28
Orem 27
Helsinki 26
North Bergen 26
Brussels 25
Frankfurt am Main 25
Montreal 25
Nuremberg 23
Palermo 23
Phoenix 23
Atlanta 22
Denver 20
Jacksonville 20
Milan 20
Stockholm 20
Tianjin 20
Johannesburg 19
Tokyo 19
Chicago 17
Dearborn 17
Mumbai 17
Seattle 17
Turku 17
Amsterdam 16
Jakarta 16
Vienna 16
Brasília 15
Houston 15
London 15
Boston 14
Brooklyn 14
Chennai 14
Columbus 14
Guangzhou 14
Naples 14
Porto Alegre 14
Rio de Janeiro 14
Jinan 13
Philadelphia 13
Boardman 12
Curitiba 12
Florence 12
Poplar 12
Tashkent 12
Toronto 12
Ben Arous 11
Campinas 11
Chengdu 11
Mexico City 11
Ann Arbor 10
Baku 10
Cagliari 10
Charlotte 10
Kameido 10
Lawrenceville 10
Lima 10
Nanjing 10
Pune 10
San Francisco 10
Suffern 10
Belo Horizonte 9
Bexley 9
Genoa 9
Istanbul 9
Shanghai 9
Shenzhen 9
Baghdad 8
Bologna 8
Caracas 8
Catania 8
Dong Ket 8
Totale 6.539
Salva come PNG Salva come JPEG
Nome #
[68 Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177 Lu]DOTATOC PRRT: The “Theragnomics” Concept 246
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 213
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 211
18F-FDG PET/CT Imaging of Immune Checkpoint Inhibitor-Related "Retroperitoneal Panniculitis" 210
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 207
PRRT Retreatments: Renal Function Evaluation 206
223RA-dichloride use in patients affected by bone metastases from castration-resistant prostate cancer: single centre experience 203
Artificial intelligence in molecular imaging: from machine to deep learning 200
18F-FACBC in prostate cancer: A systematic review and meta-analysis 198
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 192
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 187
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 186
COVID-19 Surface Persistence: A Recent Data Summary and Its Importance for Medical and Dental Settings 184
Safety, effectiveness and haematological toxicity of 223Radichloride: a single Centre experience 183
Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study 182
Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 181
Clinico-laboratory response and haematological toxicity in patients undergoing therapy with 223RA-dichloride 178
Effectiveness, safety and haematological toxicity of 223Ra-Cl2: a single centre experience 177
18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma 172
Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBI scan: A new quantitative method for improving diagnostic accuracy 171
Dual Time-Point FET-PET/CT in Glioma Patients: a Single-Centre Preliminary Experience 170
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 166
Renal Function Evaluation in PRRT Retreatments 164
Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas 161
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients 158
Comparing radioiodine abdominal absorbed dose in differentiated thyroid cancer patients undergone thyroid remnant ablation in either levo-thyroxine withdrawal or after rhtsh stimulation 157
PRRT retreatments: renal function evaluation 156
Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience 153
Artifcial intelligence applications in SSTR targeted PET/CT images: prediction of response assessment in GEP-NETs undergoing PRRT with [177Lu]DOTATOC 153
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 150
Correction to: 18F-FMISO PET imaging: insights over MRI in patients with glioma (Clinical and Translational Imaging, (2020), 8, 1, (3-10), 10.1007/s40336-019-00353-0) 145
The additional value of 18F-FDG PET and MRI in patients with glioma: A review of the literature from 2015 to 2020 138
Is dual tracer PET/CT a prognostic biomarker in the PRRT enrollment of GEP-NET patients? 136
Artificial intelligence applications in 68Ga-DOTA PETICT images: Prediction of response assessment in GEP-NETs undergoing PRRT with 177Lu-DOTATOC 136
68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement 135
Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation 133
Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination 131
Radiomics Analysis of Brain [18 F]FDG PET/CT to Predict Alzheimer’s Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of SPM Cortical Segmentation, Pyradiomics and Machine-Learning Analysis 130
Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics 125
Emerging applications of imaging in glioma: focus on PET/MRI and radiomics 124
Undetectable or low (< 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients 124
Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomics Classification for Prediction of Disease Outcome 123
PET/MR in neuro-oncology: is it ready for prime-time? 123
The utility of dual time-point FET-PET/CT in recurrence assessment of glioma patients 123
Artificial neural networks in cardiovascular diseases and its potential for clinical application in molecular imaging 119
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature 117
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review– part 2 112
[18F] Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review 112
Molecular imaging of pancreatic neoplasms 112
From bench to bedside: highlights from the International Dialogue on Ovarian Cancer 111
Sars-cov-2 persistence: data summary up to q2 2020 111
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature 110
FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature 106
Correction to: Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 106
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients 105
[11C]Choline PET/CT in a Patient with Prostate Cancer Biochemical Recurrence Showing Two Suspicious Findings in the Breast and Liver 105
Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study 105
Malignant cutaneous melanoma: Updates in PET imaging 104
[18F]FDG PET/CT criteria for treatment response assessment: EORTC and beyond 103
An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics 99
A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors 99
Non-invasive cardiac imaging in patients with systemic amyloidosis: a practical approach with emphasis on clinical contribution of bone-seeking radiotracers 99
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 95
The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence Also in Comparison with MRI 94
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI 93
Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study 92
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review—Part 1 oncological setting 92
Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer 91
Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals 90
A Review of Advances in Molecular Imaging of Rheumatoid Arthritis: From In Vitro to Clinic Applications Using Radiolabeled Targeting Vectors with Technetium-99m 89
Prognostic insights of molecular imaging in cardiac sarcoidosis 89
Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging 88
Response prediction to PRRT in progressing and metastatic GEP-NET undergoing restaging 68Ga-DOTA PETICT: A preliminary multicenter radiomics study 88
PET Imaging in Gliomas: Clinical Principles and Synergies with MRI 87
[18F]PSMA‑1007 PET/CT‑based radiomics may help enhance the interpretation of bone focal uptakes in hormone‑sensitive prostate cancer patients 87
Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs) 86
Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study 85
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score 85
Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose 80
Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics 79
ChatGPT in nuclear medicine and radiology: lights and shadows in the AI bionetwork 75
Prostate Cancer Biochemical Recurrence Resulted Negative on [68Ga]Ga-PSMA-11 but Positive on [18F]Fluoromethylcholine PET/CT 74
Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review 71
Artificial Intelligence and Statistical Models for the Prediction of Radiotherapy Toxicity in Prostate Cancer: A Systematic Review 71
Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer? 70
Correction: PSMA‑positive prostatic volume prediction with deep learning based on T2‑weighted MRI 69
PSMA-positive prostatic volume prediction with deep learning based on T2-weighted MRI 67
Reply to Perera Molligoda Arachchige AS [1] 67
[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature 67
Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features? 64
Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients 63
The role of PET radiomic features in prostate cancer: a systematic review 59
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding ­ [68Ga] Ga‑PSMA‑11 PET scans of primary prostate cancer 58
Unspecic bone uptakes in PSMA PET for prostate cancer: why do they matter? 56
The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer 54
Monitoring of cardiac transthyretin amyloid load by [Tc-99m]DPD scintigraphy: is it the end of the semi-quantitative evaluation? 54
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers 53
The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years 50
Stereotactic Radiotherapy for Penile Metastasis: Case Report and Systematic Literature Review 43
The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition 39
Totale 12.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.671
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.671
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022402 0 0 0 0 31 13 27 34 6 54 35 202
2022/20231.384 119 196 70 107 88 140 17 89 482 16 36 24
2023/2024369 41 39 22 33 43 50 13 31 9 32 16 40
2024/20252.141 12 59 45 73 151 63 151 316 506 182 282 301
2025/20266.494 443 364 381 419 549 1.430 675 809 848 348 102 126
2026/20271.157 156 218 288 468 27 0 0 0 0 0 0 0
Totale 12.413